Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 4/20 | 0.60 |
| ▸ | DRD2 | P14416 | 2/20 | 0.60 |
| ▸ | DRD3 | P35462 | 2/20 | 0.60 |
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | NPY2R | P49146 | 1/20 | 0.51 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.50 |
| ▸ | HTR7 | P34969 | 1/20 | 0.49 |
| ▸ | NCF1 | P14598 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11836396 | 0.85 | MAPT (0.74) | DRD4DRD2DRD3SIGMAR1ALDH1A1 | |
| SCHEMBL6494527 | 0.83 | MAPT (0.64) | DRD4DRD2DRD3ALDH1A1MAPT | |
| SCHEMBL4519472 | 0.81 | DRD4 (0.62) | DRD4DRD2DRD3SIGMAR1MAPT | |
| SCHEMBL6864941 | 0.80 | DRD4 (0.81) | DRD4DRD2DRD3SIGMAR1ALDH1A1 | |
| SCHEMBL3465194 | 0.80 | DRD4 (0.55) | DRD4DRD2DRD3SIGMAR1MAPT | |
| SCHEMBL19212135 | 0.79 | DRD4 (0.60) | DRD4DRD2DRD3SIGMAR1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL27955450 | 0.79 | SIGMAR1 (0.61) | DRD4DRD2DRD3SIGMAR1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL7422022 | 0.78 | PRMT1 (0.56) | DRD4DRD2DRD3SIGMAR1PRMT1 | |
| SCHEMBL21596404 | 0.78 | MAPT (0.50) | ALDH1A1MAPTSMN1; SMN2TDP1 | |
| SCHEMBL6484904 | 0.76 | DRD2 (0.53) | DRD4DRD2DRD3SIGMAR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6969712-B2 | Benzimidazole derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2005-11-29 | — | — | US | disclosed |
| US-20040044056-A1 | Benzimidazole derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2004-03-04 | — | — | US | disclosed |
| EP-1342717-A1 | BENZIMIDAZOLE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2003-09-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040044056-A1 | Benzimidazole derivatives | GPR119, OPRL1, INSR | DRD4 135/4885DRD2 139/4885DRD3 289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.